QRC-PVD Clinical Trial - Metformin Aneurysm Trial (MAT)
- Future Students
- JCU Global Experience
- International Students
- Open Day
- How to apply
- Pathways to university
- Virtual Open Day
- Living on Campus
- Courses
- Publications
- Scholarships
- Parents and Partners
- JCU Heroes Programs
- Aboriginal and Torres Strait Islander in Marine Science
- Elite Athletes
- Defence
- Current Students
- New students
- JCU Orientation
- LearnJCU
- Placements
- CEE
- Unicare Centre and Unicampus Kids
- Graduation
- Off-Campus Students
- JCU Job Ready
- Safety and Wellbeing
- JCU Prizes
- Professional Experience Placement
- Employability Edge
- Art of Academic Writing
- Art of Academic Editing
- Careers and Employability
- Student Equity and Wellbeing
- Career Ready Plan
- Careers at JCU
- Partners and Community
- JCU-CSIRO Partnership
- Alumni
- About JCU
- Reputation and Experience
- Chancellery
- Governance
- Celebrating 50 Years
- Academy
- Indigenous Engagement
- Education Division
- Graduate Research School
- Research and Teaching
- Research Division
- Research and Innovation Services
- CASE
- College of Business, Law and Governance
- College of Healthcare Sciences
- College of Medicine and Dentistry
- College of Science and Engineering
- CPHMVS
- Anthropological Laboratory for Tropical Audiovisual Research (ALTAR)
- Anton Breinl Research Centre
- Agriculture Technology and Adoption Centre (AgTAC)
- Advanced Analytical Centre
- AMHHEC
- Aquaculture Solutions
- AusAsian Mental Health Research Group
- ARCSTA
- Area 61
- Lions Marine Research Trust
- Australian Tropical Herbarium
- Australian Quantum & Classical Transport Physics Group
- Boating and Diving
- Clinical Psychedelic Research Lab
- Centre for Tropical Biosecurity
- Centre for Tropical Bioinformatics and Molecular Biology
- CITBA
- CMT
- Centre for Disaster Solutions
- CSTFA
- Cyclone Testing Station
- The Centre for Disaster Studies
- Daintree Rainforest Observatory
- Fletcherview
- JCU Eduquarium
- JCU Turtle Health Research
- Language and Culture Research Centre
- MARF
- Orpheus
- TESS
- JCU Ideas Lab
- TARL
- eResearch
- Indigenous Education and Research Centre
- Estate
- Work Health and Safety
- Staff
- Discover Nature at JCU
- Cyber Security Hub
- Association of Australian University Secretaries
- Services and Resources Division
- Environmental Research Complex [ERC]
- Foundation for Australian Literary Studies
- Gender Equity Action and Research
- General Practice and Rural Medicine
- Give to JCU
- Indigenous Legal Needs Project
- Inherent Requirements
- IsoTropics Geochemistry Lab
- IT Services
- JCU Webinars
- JCU Events
- JCU Motorsports
- JCU Sport
- Library
- Mabo Decision: 30 years on
- Marine Geophysics Laboratory
- Office of the Vice Chancellor and President
- Outstanding Alumni
- Pharmacy Full Scope
- Planning for your future
- Policy
- PAHL
- Queensland Research Centre for Peripheral Vascular Disease
- Rapid Assessment Unit
- RDIM
- Researcher Development Portal
- Roderick Centre for Australian Literature and Creative Writing
- Contextual Science for Tropical Coastal Ecosystems
- State of the Tropics
- Strategic Procurement
- Student profiles
- SWIRLnet
- TREAD
- TropEco for Staff and Students
- TQ Maths Hub
- TUDLab
- UAV
- VAVS Home
- WHOCC for Vector-borne & NTDs
- Media
- Copyright and Terms of Use
- Australian Institute of Tropical Health & Medicine
- Pay review
An abdominal aortic aneurysm (AAA) is the ballooning of part of the aorta in the abdomen. AAAs vary in size but tend to gradually grow larger. Once they reach a size of 5.5cm in diameter, they have a high chance of rupture. The cause of AAA is not known but there are some risk factors such as history of smoking, age and being male.
Currently, there are no effective drug treatments available for AAA. However, research suggests that a drug called metformin (which is used to lower blood sugar levels in people with type 2 diabetes) may reduce the risk of adverse AAA events such as AAA repair and AAA rupture. A large clinical trial is needed to test this. Metformin is a safe, well-tolerated drug that is suitable for use in a range of populations (including people without diabetes). The main aim of this clinical trial is to test if metformin reduces the risk of adverse AAA events (i.e., AAA repair or rupture).
Recruitment Status | Recruiting |
---|---|
Ethics Approval | Human Research Ethics Approval |
Participants will have an initial Screening Visit to confirm eligibility and review health and medical history. Following successful screening, participants will be randomised to either the active metformin study medication or a placebo and continue taking the study medication for approximately three and a half years. Over this time, participants will be regularly followed up by their study coordinator every three months, over the phone, and annually in person if possible. Participants in MAT will also have their routine imaging (i.e. ultrasounds from their treating hospital) collected, and repeat blood tests on occasion.
Screening |
| 1-2 hours |
---|---|---|
Pre-Randomisation | ||
Week 2 | Phone call check in with study coordinator | 10-15 minutes |
Week 6 | Phone call check in with study coordinator | 10-15 minutes |
Week 6 | Phone call check in with study coordinator | 10-15 minutes |
Randomisation | No in person visit - Study medication posted | |
3 months | Phone call check in with study coordinator | 10-15 minutes |
6 months | Phone call check in with study coordinator New study medication posted | 1-2 hours |
12 months | Health check-up:
| 1-2 hours |
The above study schedule, from 3 months will repeat for the duration of participation (typically 3.5 - 4 years).
How to participate
Participant Information Flyer and Consent Forms
Register your interest in participating in this study.